Literature DB >> 22122056

γ-Secretase inhibitors and modulators for Alzheimer's disease.

Michael S Wolfe1.   

Abstract

γ-Secretase is a membrane embedded aspartyl protease complex with presenilin as the catalytic component. Along with β-secretase, this enzyme produces the amyloid β-protein of Alzheimer's disease (AD) from the amyloid β-protein precursor. Because of its key role in the pathogenesis of AD, γ-secretase has been a prime target for drug discovery, and many inhibitors of this protease have been developed. The therapeutic potential of these inhibitors is virtually negated by the fact that γ-secretase is an essential part of the Notch signaling pathway, rendering the compounds unacceptably toxic upon chronic exposure. However, these compounds have served as useful chemical tools for biological investigations. In contrast, γ-secretase modulators continue to be of keen interest as possible AD therapeutics. These modulators either shift amyloid β-protein production to shorter, less pathogenic peptides or inhibit the proteolysis of amyloid β-protein precursor selectively compared to that of Notch. The various chemical types of inhibitors and modulators will be discussed, along with their use as probes for basic biology and their potential as AD therapeutics.
© 2011 The Author. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122056      PMCID: PMC3254709          DOI: 10.1111/j.1471-4159.2011.07501.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  43 in total

Review 1.  Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.

Authors:  Casper Groth; Mark E Fortini
Journal:  Semin Cell Dev Biol       Date:  2012-01-30       Impact factor: 7.727

2.  Cutting in on a secretase pas de deux.

Authors:  Michael S Wolfe
Journal:  Cell Res       Date:  2015-09-11       Impact factor: 25.617

3.  Small molecules intercept Notch signaling and the early secretory pathway.

Authors:  Andreas Krämer; Torben Mentrup; Bertrand Kleizen; Eric Rivera-Milla; Daniela Reichenbach; Christoph Enzensperger; Richard Nohl; Eric Täuscher; Helmar Görls; Aspasia Ploubidou; Christoph Englert; Oliver Werz; Hans-Dieter Arndt; Christoph Kaether
Journal:  Nat Chem Biol       Date:  2013-09-29       Impact factor: 15.040

4.  α-Mangostin decreases β-amyloid peptides production via modulation of amyloidogenic pathway.

Authors:  Lan-Xue Zhao; Yan Wang; Ting Liu; Yan-Xia Wang; Hong-Zhuan Chen; Jian-Rong Xu; Yu Qiu
Journal:  CNS Neurosci Ther       Date:  2017-04-21       Impact factor: 5.243

5.  DAPT, a potent Notch inhibitor regresses actively growing abdominal aortic aneurysm via divergent pathways.

Authors:  Chetan P Hans; Neekun Sharma; Rishabh Dev; Jones M Blain; Jeff Tonniges; Gunjan Agarwal
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

6.  Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data.

Authors:  Camilla Niva; Joanna Parkinson; Fredrik Olsson; Erno van Schaick; Johan Lundkvist; Sandra A G Visser
Journal:  Eur J Clin Pharmacol       Date:  2013-01-04       Impact factor: 2.953

7.  γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.

Authors:  Fei Liu; Zhi-Qin Xue; Si-Hao Deng; Xiong Kun; Xue-Gang Luo; Peter R Patrylo; Gregory M Rose; Huaibin Cai; Robert G Struble; Yan Cai; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2013-02-22       Impact factor: 3.386

8.  Initial Optimization of a New Series of γ-Secretase Modulators Derived from a Triterpene Glycoside.

Authors:  Nathan O Fuller; Jed L Hubbs; Wesley F Austin; Steffen P Creaser; Timothy D McKee; Robyn M B Loureiro; Barbara Tate; Weiming Xia; Jeffrey L Ives; Mark A Findeis; Brian S Bronk
Journal:  ACS Med Chem Lett       Date:  2012-08-29       Impact factor: 4.345

9.  Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.

Authors:  Juliette Janson; Susanna Eketjäll; Karin Tunblad; Fredrik Jeppsson; Stefan Von Berg; Camilla Niva; Ann-Cathrin Radesäter; Johanna Fälting; Sandra A G Visser
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

Review 10.  Development and mechanism of γ-secretase modulators for Alzheimer's disease.

Authors:  Christina J Crump; Douglas S Johnson; Yue-Ming Li
Journal:  Biochemistry       Date:  2013-05-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.